Dr. Jay P. Lopez, MD
Hematology & Oncology (Hematology & Oncology Physician)
21632 Highway 99
Edmonds, WA 98026
Who else practices at this address →
Snohomish County includes primary care (7% of residents) and dental (8% of residents) and mental health (36% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Years since graduation
- 14
- In the NPI registry since
- 2012
- Medicare patients seen, 2024
- 235
Licensed in Washington since 2018, according to the Washington State Department of Health. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2012Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology & Oncology Physician primary
WA license MD60875633 (first issued 2018; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Swedish Medical Center Seattle, WA
- Providence Regional Medical Center Everett Everett, WA
- Swedish Edmonds Hospital Edmonds, WA
Medical groups
- Swedish Health Services (1,037 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 235
- Services billed
- 1,181
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 445 | 193 |
| Established patient office or other outpatient visit, 40-54 minutes | 182 | 50 |
| Established patient office or other outpatient visit, 20-29 minutes | 65 | 53 |
| New patient office or other outpatient visit, 60-74 minutes | 31 | 31 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Anastrozole Other prescribers in Edmonds, WA | 115 |
| Prednisone Other prescribers in Edmonds, WA | 91 |
| Potassium Chloride Other prescribers in Edmonds, WA | 79 |
| Abiraterone Acetate | 77 |
| Eliquis (apixaban) Other prescribers in Edmonds, WA | 63 |
| Gabapentin Other prescribers in Edmonds, WA | 62 |
| Dexamethasone Other prescribers in Edmonds, WA | 61 |
| Prochlorperazine Maleate Other prescribers in Edmonds, WA | 59 |
| Acyclovir Other prescribers in Edmonds, WA | 53 |
| Warfarin Sodium Other prescribers in Edmonds, WA | 47 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 9 payments worth $4,101 in total to this clinician.
| Eisai Inc. | $2,400 |
|---|---|
| Genmab U.S., Inc. | $1,506 |
| Boston Scientific Corporation | $142 |
| Daiichi Sankyo Inc. | $37.66 |
| Adc Therapeutics America, Inc. | $15.99 |
| Consulting Fee | $3,765 |
|---|---|
| Food and Beverage | $323 |
| Travel and Lodging | $13.30 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Eisai Inc. Nov 18, 2025 | Consulting Fee Lenvima · Oncology | $2,400 |
| Genmab U.S., Inc. May 22, 2025 | Consulting Fee Epkinly · Oncology | $1,365 |
| Genmab U.S., Inc. May 22, 2025 | Travel and Lodging Epkinly · Oncology · travel to Seattle, WA | $13.30 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $26,065 in research payments for these studies, mostly to the institutions running them.
- Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
AbbVie Inc. · Active, not recruiting · NCT06191744
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.